These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Fluvoxamine as effective as clomipramine against symptoms of severe depression: results from a multicentre, double-blind study. Zohar J; Keegstra H; Barrelet L Hum Psychopharmacol; 2003 Mar; 18(2):113-9. PubMed ID: 12590404 [TBL] [Abstract][Full Text] [Related]
49. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. Matsunaga H; Nagata T; Hayashida K; Ohya K; Kiriike N; Stein DJ J Clin Psychiatry; 2009 Jun; 70(6):863-8. PubMed ID: 19422759 [TBL] [Abstract][Full Text] [Related]
50. Comparing the Effects of a Herbal Drug based on Noras MR; Soltanifar A; Salari R; Jarahi L; Abrishami MH Curr Drug Discov Technol; 2022; 19(5):e240622206368. PubMed ID: 35748547 [TBL] [Abstract][Full Text] [Related]
51. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. McDougle CJ; Goodman WK; Leckman JF; Lee NC; Heninger GR; Price LH Arch Gen Psychiatry; 1994 Apr; 51(4):302-8. PubMed ID: 8161290 [TBL] [Abstract][Full Text] [Related]
52. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study. Zheng H; Jia F; Han H; Wang S; Guo G; Quan D; Li G; Huang H Eur Neuropsychopharmacol; 2019 Mar; 29(3):397-404. PubMed ID: 30595354 [TBL] [Abstract][Full Text] [Related]
53. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. Maina G; Albert U; Salvi V; Bogetto F J Clin Psychiatry; 2004 Oct; 65(10):1365-71. PubMed ID: 15491240 [TBL] [Abstract][Full Text] [Related]
54. [Obsessive-compulsive disorder, frontostriatal system and the effect of the serotonergic system]. Baving L; Schmidt MH Z Kinder Jugendpsychiatr Psychother; 2000 Feb; 28(1):35-44. PubMed ID: 10746297 [TBL] [Abstract][Full Text] [Related]
55. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder. Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069 [TBL] [Abstract][Full Text] [Related]
56. Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients. Kamijima K; Murasaki M; Asai M; Higuchi T; Nakajima T; Taga C; Matsunaga H Psychiatry Clin Neurosci; 2004 Aug; 58(4):427-33. PubMed ID: 15298657 [TBL] [Abstract][Full Text] [Related]
57. Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions. Goodman WK; Ward H; Kablinger A; Murphy T J Clin Psychiatry; 1997; 58 Suppl 5():32-49. PubMed ID: 9184625 [TBL] [Abstract][Full Text] [Related]
58. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Goodman WK; Price LH; Delgado PL; Palumbo J; Krystal JH; Nagy LM; Rasmussen SA; Heninger GR; Charney DS Arch Gen Psychiatry; 1990 Jun; 47(6):577-85. PubMed ID: 2112374 [TBL] [Abstract][Full Text] [Related]
59. Combination of clomipramine and nortriptyline in the treatment of obsessive-compulsive disorder: a double-blind, placebo-controlled trial. Noorbala AA; Hosseini SH; Mohammadi MR; Akhondzadeh S J Clin Pharm Ther; 1998 Apr; 23(2):155-9. PubMed ID: 9786103 [TBL] [Abstract][Full Text] [Related]
60. Antidepressant-induced hypomania in obsessive-compulsive disorder. Rihmer Z; Barsi J; Belsõ N; Pestality P; György S Int Clin Psychopharmacol; 1996 Sep; 11(3):203-5. PubMed ID: 8923100 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]